Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 versus salmeterol/fluticasone + tiotropium in uncontrolled asthma
2017-000136-34Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate, salmeterol, fluticasone propionate and tiotropium in asthma (3 arms), sponsored by Novartis. Primary endpoint: Change from baseline in Asthma Quality of Life Questionnaire total score. Started Nov 2017; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoatesalmeterolfluticasone propionatetiotropium
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-000136-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000136-34.